Compare KOS & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KOS | OGN |
|---|---|---|
| Founded | 2003 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2011 | 2020 |
| Metric | KOS | OGN |
|---|---|---|
| Price | $2.65 | $13.52 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 6 | 5 |
| Target Price | $1.91 | ★ $11.40 |
| AVG Volume (30 Days) | ★ 16.4M | 2.4M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 0.60% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.55 |
| Revenue | $1,288,352,000.00 | ★ $6,216,000,000.00 |
| Revenue This Year | $27.11 | $0.45 |
| Revenue Next Year | N/A | $1.67 |
| P/E Ratio | ★ N/A | $24.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.84 | $5.69 |
| 52 Week High | $3.34 | $13.60 |
| Indicator | KOS | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 58.95 | 62.43 |
| Support Level | $2.33 | $13.46 |
| Resistance Level | $2.69 | $13.60 |
| Average True Range (ATR) | 0.18 | 0.04 |
| MACD | 0.06 | -0.03 |
| Stochastic Oscillator | 95.54 | 46.15 |
Kosmos Energy Ltd is a deepwater exploration and production company focused on meeting the world's growing demand for energy. It has diversified oil and gas production from assets offshore Ghana, Equatorial Guinea, Mauritania, Senegal and the Gulf of America. The Company had operations in four geographic reporting segments: Ghana, Equatorial Guinea, Mauritania/Senegal and the Gulf of America. The majority of revenue is derived from the Ghana segment.
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.